From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Silence Therapeutics – how’s “transformational deal” partner? Red flags really fluttering?

By Steve Moore | Wednesday 13 November 2019


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Having as recently as June been sub 50p, shares in self-styled “a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases” Silence Therapeutics (SLN) spiked above 100p in July on the back of announcements of a collaboration with, and investment from, Mallinckrodt (NYSE - MNK). The shares have in the last month sparked significantly further – to a current near 400p, giving a more than £300 million market cap. However…

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

CTAI

Catenai – monster dilution

Time left: 19:02:25